Over the last 12 months, six Outlook Therapeutics, Inc. insiders bought into shares with their own money, about $7.9 million in total, and none of them sold.
GMS Ventures & Investments (Director) made the biggest buy, worth around $5 million.
On the institutional side, 69 funds reported holding OTLK at the end of Q2 2026, and more funds bought than sold. Zooming out by quarter: 2 quarters in a row of net buying by insiders. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Sukhtian Ghiath M. | Director | Buy | 2,525,252 | $0.99 | $2.5M | SEC |
| Jul 29, 2026 | Sukhtian Faisal Ghiath | Director | Buy | 95,398 | $1.05 | $100K | SEC |
| Jun 3, 2026 | Haddadin Yezan Munther | Director | Buy | 29,000 | $0.83 | $24K | SEC |
| Jun 1, 2026 | GMS Ventures & Investments | Director | Buy | 8,539,709 | $0.59 | $5.0M | SEC |
| May 27, 2026 | Sukhtian Faisal Ghiath | Director | Buy | 122,174 | $0.41 | $50K | SEC |
| May 27, 2026 | Haddadin Yezan Munther | Director | Buy | 34,000 | $0.44 | $15K | SEC |
| May 27, 2026 | THURMAN RANDY H | Director | Buy | 5,000 | $0.43 | $2K | SEC |
| May 27, 2026 | HILZINGER KURT J | Director | Buy | 400,000 | $0.44 | $176K | SEC |
| Sep 30, 2024 | KENYON LAWRENCE A | CFO | Buy | 5,000 | $5.69 | $28K | SEC |
| Mar 29, 2024 | Haddadin Yezan Munther | Director | Buy | 1,882 | $11.82 | $22K | SEC |
| Mar 11, 2024 | Evanson Jeff | Executive Officer | Buy | 62,484 | $0.42 | $26K | SEC |
| Apr 21, 2023 | Dagnon Terry | Executive Officer | Sell | 520,000 | $1.14 | $593K | SEC |
| Jan 24, 2023 | Evanson Jeff | Executive Officer | Sell | 267,000 | $1.11 | $296K | SEC |
| Jan 19, 2023 | Evanson Jeff | Executive Officer | Sell | 103,255 | $1.22 | $126K | SEC |
| Jan 19, 2023 | Evanson Jeff | Executive Officer | Sell | 27,162 | $1.31 | $36K | SEC |
In the last 12 months Outlook Therapeutics, Inc. insiders made open-market purchases worth about $7.9 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in OTLK was filed on 2026-08-14.
69 investment managers reported holding OTLK in SEC Form 13F filings for Q2 2026.
No congressional trades in OTLK were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).